Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company’s bottom-line figure.

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...

The collaboration is the first initiated under Flagship's Pioneering Medicines strategic partnership with Pfizer Inc. announced in July 2023. "We are thrilled to be part of the Flagship and Pfizer ...

“In the Gulf, we are committed to accelerating the availability of global innovations while fostering partnerships with governments, healthcare providers, and key stakeholders,” Serhat ...

Principal Secretary Ouma Oluga and Pfizer Global President for Emerging Markets Nick Lagunowich on Tuesday unveiled the Pfizer Accord in Nairobi.The partnership under the Accord for a Healthier ...

Pfizer is extending its partnership with medtech company CytoReason to use CytoReason’s artificial intelligence in the drug discovery process. As part of the partnership, Pfizer will make a $20 ...

Article ‘Count’ and ‘Share’ for Pfizer Global Research & Development, France based on listed parameters only. The articles listed below published by authors from Pfizer Global Research ...

Pfizer Pharmaceuticals Global B.V., Netherlands Time frame: 1 May 2023 - 30 April 2024 Research. Overall research output. Count ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets Decision comes two years after acquiring the drug’s parent company, Global Blood Therapeutic, in a $5.4 billion deal By ...